Home > The Pipeline of Novel Antituberculosis Agents
The Pipeline of Novel Antituberculosis Agents
Prof Andreas H. Diacon
Professof of Physiology & Principal Specialist in Pulmonolgy
University of Stellenbosch and Tygerberg Academic Hospital
Host: Prof Valerie Mizrahi [IDM Director/MMRU]
Professor Andreas Diacondeveloped an early interest in tuberculosis during training in a former TB sanatorium in Davos in the Swiss Alps, also named the “magic mountain”. After migrating to South Africa, he started his own anti-tuberculosis drug research. He is the founder and CEO of TASK, an organisation specialising in clinical studies with novel TB treatments, vaccines and diagnostics. Many novel compounds have since been tested at TASK research sites. His main research interests now lie in the techniques and clinical methods for the evaluation of novel anti-tuberculosis agents. He is engaged in various research collaborations within South Africa and with the USA and Europe.
Recently Andreas Diacon was named as one of Bill Gates’s Heroes in the Field through his contributions and continuing search for better treatment solutions for tuberculosis.